CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction
with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016
financial results press release, you are invited to listen to a
conference call that will be broadcast live over the internet on
Tuesday, March 14, 2017 at
4:30 pm Eastern Time (1:30 pm Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 1 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury and chronic metabolic diseases such as
nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH) and other liver diseases both broad and
orphan. DURECT's advanced oral, injectable, and transdermal
delivery technologies are designed to enable new indications and
enhanced attributes for small-molecule and biologic drugs.
One late-stage product candidate in this category is
POSIMIR® (SABER®-Bupivacaine), an
investigational analgesic product intended to address key unmet
needs in postoperative pain management. Another late stage
product candidate is REMOXY® ER (oxycodone), an
investigational new drug based on DURECT's ORADUR®
technology. For more information, please visit
www.durect.com.
NOTE: POSIMIR®, SABER®, and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, REMOXY ER and DUR-928, are investigational drugs under
development and have not been approved for sale by the U.S. Food
and Drug Administration or other health authorities.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-fourth-quarter-2016-earnings-conference-call-300413482.html
SOURCE DURECT Corporation